CRISPR Therapeutics AG
CRSP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.97B
Close$
$-0.48
100.9% downside
Current Fair Value
100.9% downsideOvervalued by 100.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.97 Billion |
|---|---|
| Enterprise Value | $5.48 Billion |
| Earnings per Share | $-6.47 |
| Beta | 1.76 |
| Outstanding Shares | 96,514,102 |
Return
| Return on Equity | -25.83% |
|---|---|
| Return on Assets | -17.02% |
| Return on Invested Capital | -20.08% |
Valuation & Multiples
| P/E Ratio | -10.8 |
|---|---|
| PEG | 19.19 |
| Price to Sales | - |
| Price to Book Ratio | 2.88 |
| Enterprise Value to Revenue | 409.16 |
| Enterprise Value to EBIT | -10.84 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.46 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS Estimate
$-1.04
Consensus analyst estimateRevenue Estimate
$14.75 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 11, 2027
EPS Estimate
$-1.21
Consensus analyst estimateRevenue Estimate
$10.69 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 94.37% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.14%▼ 77.05% |
|---|---|
| Total Invested | $168.65M▼ 96.00% |
| Investors Holding | 160▼ 398.00% |
About CRISPR Therapeutics AG
CEO: Samarth Kulkarni
